A single-arm, multicenter phase I dose escalation trial 91 enrolled 20 patients with sarcomas, melanomas, and ovarian cancers to evaluate the safety of an OAV (TILT-123), which encoded TNF-α and IL-2 in combination with TIL therapy. Here, IL2 is linked to melanoma.